We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current KALV market cap is 432.9M. The company's latest EPS is USD -2.5627 and P/E is -3.42.
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -29.09M | -29.75M | -33.15M | -48.46M | -44.22M |
| Net Income | -25.32M | -27.65M | -29.03M | -44.65M | -40.44M |
| Year End 30 April 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 12.69M | 0 | 0 | 0 | 0 |
| Operating Income | -40.53M | -57.92M | -96.61M | -110.87M | -140.45M |
| Net Income | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M |
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 160.33M | 138.74M | 113.97M | 235.4M | 200.2M |
| Total Liabilities | 21M | 24.3M | 25.39M | 28.82M | 27.4M |
| Total Equity | 139.34M | 114.45M | 88.58M | 206.58M | 172.8M |
| Year End 30 April 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 92.53M | 272.01M | 203.88M | 183.2M | 235.4M |
| Total Liabilities | 8.78M | 14.82M | 18.79M | 22.18M | 28.82M |
| Total Equity | 83.75M | 257.19M | 185.09M | 161.03M | 206.58M |
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -26.73M | -46.56M | -74.13M | -89.23M | -40.22M |
| Investing | 19.61M | 48.17M | 41.47M | -84.72M | 37.16M |
| Financing | 204k | 332k | 616k | 150.71M | 3M |
| Year End 30 April 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -44.82M | -30.17M | -78.13M | -75.26M | -89.23M |
| Investing | 16.75M | -147.65M | 57.86M | 41.42M | -84.72M |
| Financing | 11.58M | 212.12M | 1.58M | 58.12M | 150.71M |
| Market Cap | 432.9M |
| Price to Earnings Ratio | -3.42 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 13.62 |
| Price to Book Ratio | 2.1 |
| Dividend Yield | - |
| Shares Outstanding | 49.42M |
| Average Volume (1 week) | 684.16k |
| Average Volume (1 Month) | 415.73k |
| 52 Week Change | -25.38% |
| 52 Week High | 16.88 |
| 52 Week Low | 7.97 |
| Spread (Intraday) | 0.37 (4.16%) |
| Company Name | KalVista Pharmaceuticals Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.kalvista.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
